Host-directed therapies against tuberculosis
- PMID: 24503259
- DOI: 10.1016/S2213-2600(13)70295-9
Host-directed therapies against tuberculosis
Comment on
-
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial.Lancet Respir Med. 2014 Feb;2(2):108-22. doi: 10.1016/S2213-2600(13)70234-0. Epub 2014 Jan 9. Lancet Respir Med. 2014. PMID: 24503266 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
